🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Effect of Hypnosis in the Management of Anxiety and Chemo-induced Symptoms in Adolescents and Young Adults With Sarcoma or Germ Cell Tumor and in Young Women With Breast Cancer

RecruitingNAAges 15 Years - 49 YearsAllInstitut Bergonié
NCT07614620 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The HYPNO-AJA 2 study is a prospective single-center interventional clinical trial conducted at the Institut Bergonié to evaluate the effectiveness of hypnosis in reducing anxiety and chemotherapy-related symptoms in adolescents, young adults (AYAs), and young women undergoing cancer treatment. The study focuses on patients aged 15-39 with sarcoma or germ cell tumors and women aged 15-49 with breast cancer receiving neoadjuvant chemotherapy. Cancer treatment in AYAs is frequently associated with high levels of psychological distress, particularly anxiety related to chemotherapy sessions, invasive procedures, and repeated hospitalizations. Previous studies suggest that hypnosis may help reduce anxiety, pain, nausea, and emotional distress in oncology patients, but evidence remains limited in AYA populations and specific cancer types such as sarcoma, germ cell tumors, and breast cancer. H

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Newly diagnosed patients receiving initial care and follow-up at the Institut Bergonié during treatment: 1. Adolescents or young adults (AJA) aged 15 to 39 with soft tissue or bone sarcoma or a germ cell tumor (testicular, ovarian), 2. Young women aged 15 to 49 with breast cancer. 2. Treatment with neoadjuvant chemotherapy based on anthracyclines and/or alkylating agents. 3. Treatment administered as: 1. Inpatient for patients with soft tissue or bone sarcoma or a germ cell tumor (testicular, ovarian), 2. Outpatient or day hospital for female patients with breast cancer. 4. Dated and signed informed consent (if the patient is a minor, consent must also be signed by the legal guardians). 5. Patient enrolled in a social security program in accordance with current regulations. Exclusion Criteria: 1. Known contraindications to hypnosis (psychotic disorders, mental disorders, confusion, deafness, severe cognitive impairment, etc.) 2. Patients who have already undergone hypnosis sessions within 6 months prior to enrollment. 3. Geographic, social, or psychological factors rendering the patient unable to comply with the study's follow-up and procedures. 4. Patients who are deprived of their liberty or subject to a legal protection measure (guardianship, conservatorship, judicial protection, or family authorization).
💊

What it tests

  • HYPNOSIS
📍

Where

1 site
Institut Bergonie
Bordeaux, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy